MOLECULAR MECHANISMS OF MALIGNANT TRANSFORMATION
恶性转化的分子机制
基本信息
- 批准号:2463644
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
To understand the mechanisms of malignant transformation at molecular
level, we have devised a strategy to isolate novel oncogenes using an
efficient expression cloning system. Through analysis of the signaling
pathways utilized by the oncogenes which were isolated by this
strategy, we are attempting to clarify the molecular mechanisms of
malignant transformation. In this fiscal year, the following two new
oncogenes were isolated and characterized in detail.
(1) A novel oncogene, designated NET1, was isolated from a human
neuroepithelioma cell line. The NET1 cDNA encoded a predicted protein
species of 54 kDa containing the Dbl-Homology motif, which is
implicated as regulators of small GTP-binding proteins. The NET1
oncogene cDNA was activated by 5'-truncation, since a full- length cDNA
encoding the NET1 proto-oncogene did not display transforming
potential. The NET1 transcripts were ubiquitously expressed in all the
tissues examined. Using fluorescence in situ hybridization, we
localized the NET1 gene to the short arm of human chromosome 10 at band
p15. (2) A constitutively active form of fibroblast growth factor
receptor 2 (FGFR2) was identified in osteosarcoma cells. Unlike other
tyrosine kinase receptors activated by N-terminal truncation in tumors,
this receptor, FGFR2-ROS, contains an altered C-terminus generated from
chromosomal rearrangement with a novel gene, designated FRAG1. While
the removal of the C-terminus slightly activates FGFR2, the presence
of the FRAG1 sequence dramatically stimulates the transforming activity
and autophosphorylation of the receptor. FGFR2-ROS is expressed as a
unusually large protein and is highly phosphorylated in NIH 3T3
transfectants. FRAG1 is ubiquitously expressed and encodes a predicted
protein of 27 kDa lacking significant structural similarity to known
proteins. FRAG1 protein showed a perinuclear localization consistent
with expression in the Golgi complex. The highly activated state of
FGFR2-ROS appears to be attributed to constitutive dimer formation and
higher phosphorylation level as well as possibly altered subcellular
localization. These results indicate a unique mechanism of receptor
activation by a C-terminus alteration through a chromosomal fusion with
FRAG1.
从分子水平认识恶性转化的机制
水平,我们已经设计了一种策略来分离新的癌基因,使用
高效的表达克隆系统。通过对信令的分析
被分离出来的癌基因所利用的途径
策略,我们正试图澄清的分子机制
恶变。在本财年,以下两项新的
对癌基因进行了分离和详细鉴定。
(1)从人类中分离到一个新的癌基因,命名为Net1
神经上皮瘤细胞系。Net1基因编码一个预测的蛋白质
含有DBL-同源基序的54 kDa物种,这是
被认为是小的GTP结合蛋白的调节者。网络1
癌基因c DNA被5‘-截断激活,因为一个全长的c DNA
编码Net1原癌基因不显示转化
潜力。Net1转录本在所有的
组织检查。利用荧光原位杂交,我们
将Net1基因定位于人类10号染色体短臂的带上
第15页。(2)构成活性形式的成纤维细胞生长因子
骨肉瘤细胞表达受体2(FGFR2)。不同于其他
肿瘤中N端截断激活的酪氨酸激酶受体,
这种受体,FGFR2-ROS,含有一个改变的C末端,产生于
一种新基因的染色体重排,命名为FRAG1。而当
C末端的去除略微激活了FGFR2,即
极大地刺激了FRAG1序列的转化活性
和受体的自动磷酸化。FGFR2-ROS表示为
异常大的蛋白质,在NIH3T3中高度磷酸化
转染者。FRAG1被无处不在地表达并编码预测的
27 kDa的蛋白质与已知蛋白质缺乏显著的结构相似性
蛋白质。FRAG1蛋白显示核周定位一致
在高尔基复合体中表达。高度活跃的状态
FGFR2-ROS似乎归因于结构性二聚体的形成和
更高的磷酸化水平以及可能的亚细胞变化
本地化。这些结果表明了一种独特的受体机制。
通过与染色体融合的C-末端改变而激活
FRAG1。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
T MIKI其他文献
T MIKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('T MIKI', 18)}}的其他基金
SIGNAL TRANSDUCTION THROUGH THE ECT2 ONCOGENE PRODUCT
通过 ECT2 癌基因产品的信号转导
- 批准号:
3774842 - 财政年份:
- 资助金额:
-- - 项目类别:
ISOLATION OF NOVEL ONCOGENES BY AN EFFICIENT EXPRESSION CLONING SYSTEM
通过高效表达克隆系统分离新型癌基因
- 批准号:
3752681 - 财政年份:
- 资助金额:
-- - 项目类别:
CLONING AND CHARACTERIZATION OF NEW PROTEIN TYROSINE PHOSPHATASES
新蛋白酪氨酸磷酸酶的克隆和表征
- 批准号:
3774919 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF EXPRESSION CLONING SYSTEM FOR ONCOGENE CDNAS
癌基因 CDNAS 表达克隆系统的开发
- 批准号:
3838399 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF EXPRESSION CLONING SYSTEM FOR ONCOGENE CDNAS
癌基因 CDNAS 表达克隆系统的开发
- 批准号:
3916899 - 财政年份:
- 资助金额:
-- - 项目类别:
CHARACTERIZATION OF TST, THE EIGHTH MEMBER OF THE FGF GENE FAMILY
FGF 基因家族第八个成员 TST 的特征
- 批准号:
3752787 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF EXPRESSION CLONING SYSTEM FOR ONCOGENE CDNAS
癌基因 CDNAS 表达克隆系统的开发
- 批准号:
3874710 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF EXPRESSION CLONING SYSTEM FOR ONCOGENE CDNAS
癌基因 CDNAS 表达克隆系统的开发
- 批准号:
3853489 - 财政年份:
- 资助金额:
-- - 项目类别:
ISOLATION OF NOVEL ONCOGENES BY AN EFFICIENT EXPRESSION CLONING SYSTEM
通过高效表达克隆系统分离新型癌基因
- 批准号:
5201509 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
-- - 项目类别: